In a pragmatic cluster non-randomized trial, Alexandra Kulinkina and colleagues investigate the effectiveness of a clinical decision support algorithm for guiding antibiotic prescribing in pediatric ...

In case you had any doubt, Elon Musk’s X has an algorithm that favors conservative content posted by political activists over liberal content or posts by traditional news media accounts, according to ...

We now have our own terminal tournament featuring a competition for data scientists, analysts, and engineers. New details emerge about Tiger Woods' DUI arrest What Joseph Duggar told wife Kendra ...

Instagram is back with a new feature that will allow users to "tune" their algorithm to only display the content they prefer to see, which will be first made available to Reels. The feature is still ...

A few years back, Google made waves when it claimed that some of its hardware had achieved quantum supremacy, performing operations that would be effectively impossible to simulate on a classical ...

LinkedIn support accidentally revealed its algorithm: it tracks "viewer tolerance," reducing visibility for authors whose posts are consistently ignored. To succeed, diversify content types weekly, ...

So far, 2025 has been a 50-50 year for the 5-year-old mare Randomized . Klaravich Stables' daughter of Nyquist is a multiple grade 1 winner, but she has turned in four efforts that can be categorized ...

TikTok engages more than 170 million Americans with its endless scroll and viral content, but as a potential sale for the popular platform nears, experts are concerned about the future of the app's ...

Researchers have successfully used a quantum algorithm to solve a complex century-old mathematical problem long considered impossible for even the most powerful conventional supercomputers. The ...

LinkedIn's algorithm prioritizes ads & sponsored content, hurting organic reach for creators. To adapt: share niche expertise, use authentic images, craft strong hooks, write longer comments, engage ...

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.